Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance

Molecular and Biochemical Parasitology

Volumn 92, Issue 2, 1998, Pages

  De Pécoulas, Philippe Eldin ^a   Tahar, Rachida ^a   Ouatas, Taoufik ^a   Mazabraud, André ^a   Basco, Leonardo K ^a,b  

^a CNRS   (France)

^b Inst Francais de Rech S   (Cameroon)

Author keywords

Dihydrofolate reductase; Drug resistance; Malaria; Plasmodium falciparum; Polymorphism; Pyrimethamine

Indexed keywords

DIHYDROFOLATE REDUCTASE; PYRIMETHAMINE; THYMIDYLATE SYNTHASE;

ARTICLE; DNA POLYMORPHISM; GENE MUTATION; GENE SEQUENCE; MALARIA; NUCLEOTIDE SEQUENCE; PLASMODIUM VIVAX; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIMALARIALS; BASE SEQUENCE; DNA, PROTOZOAN; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; MOLECULAR SEQUENCE DATA; PLASMODIUM VIVAX; POINT MUTATION; POLYMERASE CHAIN REACTION; PYRIMETHAMINE; SEQUENCE ALIGNMENT; TETRAHYDROFOLATE DEHYDROGENASE; VARIATION (GENETICS);

EID: 0032078232     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-6851(97)00247-8     Document Type: Article

References (37)

1. [1] Wernsdorfer WH, Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther 1991;50:95-121.
2. [2] Young MD, Burgess RW. Pyrimethamine resistance in Plasmodium vivax malaria. Bull WHO 1959;20:27-36.
3. [3] Maberti S. Desarrollo de resistencia a la pirimetamina: Presentation de 15 casos estudiados en Trujillo, Venezuela. Archiv Venezol Med Trop Parasitol Méd 1960;3:239-59.
4. [4] Peters W. Chemotherapy and drug resistance in malaria, Second edition. London: Academic Press, 1987.
5. [5] Walter RD. Folate metabolism as a target for chemotherapy of malaria. In: Coombs GH, North MJ, editors. Biochemical Protozoology. London: Taylor and Francis, 1991:560-8.
6. [6] Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 1988;85:9109-13.
7. [7] Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 1988;85:9114-8.
8. [8] Zolg JW, Plitt JR, Chen GX, Palmer S. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol 1989;36:253-62.
9. [9] Cowman AF, Lew AM. Chromosomal rearrangements and point mutations in the DHFR-TS gene of Plasmodium chabaudi under antifolate selection. Mol Biochem Parasitol 1990;42:21-30.
10. [10] Hyde JE. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther 1990;48:45-59.
11. [11] Van Dijk MR, McConkey GA, Vinkenoog R, Waters AP, Janse CJ. Mechanisms of pyrimethamine resistance in two different strains of Plasmodium berghei. Mol Biochem Parasitol 1994;68:167-71.
12. [12] Basco LK, Eldin de Pécoulas P, Wilson CM, Le Bras J, Mazabraud A. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 1995;69:135-8.
13. [13] Eldin de Pécoulas P, Basco LK, Le Bras J, Mazabraud A. Association between antifol resistance in vitro and DHFR point mutation in Plasmodium falciparum isolates. Trans R Soc Trop Med Hyg 1996;90:181-2.
14. [14] Banyal HS, Inselburg J. Plasmodium falciparum: Induction, selection and characterization of pyrimethamine-resistant mutants. Exp Parasitol 1986;62:61-70.
15. [15] Inselburg J, Bzik DJ, Horii T. Pyrimethamine resistant Plasmodium falciparum: Overproduction of dihydrofolate reductase by a gene duplication. Mol Biochem Parasitol 1987;26:121-34.
16. [16] Cowman AF, Lew AM. Antifolate drug selection results in duplication and rearrangement of chromosome 7 in Plasmodium chabaudi. Mol Cell Biol 1989;9:5182-8.
17. [17] Tanaka M, Gu HM, Bzik DJ, Li WB, Inselburg JW. Dihydrofolate reductase mutations and chromosomal changes associated with pyrimethamine resistance of Plasmodium falciparum. Mol Biochem Parasitol 1990;39:127-34.
18. [18] Tanaka M, Gu HM, Bzik DJ, Li WB, Inselburg JW. Mutant dihydrofolate reductase-thymidylate synthase genes in pyrimethamine-resistant Plasmodium falciparum with polymorphic chromosome duplications. Mol Biochem Parasitol 1990;42:83-92.
19. [19] Thaithong S, Chan SW, Songsomboon S, et al. Pyrimethamine resistant mutations in Plasmodium falciparum. Mol Biochem Parasitol 1992;52:149-58.
20. [20] Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol 1993;58:283-92.
21. [21] Tahar R, Basco LK. Detection of Plasmodium ovale malaria parasites by species-specific 18 S rRNA gene amplification., Mol Cell Probes 1997 (in press).
22. [22] Tahar R, Ringwald P, Basco LK. Diagnosis of Plasmodium malariae infection by the polymerase chain reaction. Trans R Soc Trop Med Hyg 1997;91:410-1.
23. [23] Bzik DJ, Li WB, Horii T, Inselburg J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA 1987;84:8360-4.
24. [24] Snewin VA, England SM, Sims PFG, Hyde JE. Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene 1989;76:41-52.
25. [25] Cheng Q, Saul A. The dihydrofolate reductase domain of rodent malarias: Point mutations and pyrimethamine resistance. Mol Biochem Parasitol 1994;65:361-3.
26. [26] Basco LK, Le Bras J. Short-term in vitro culture of Plasmodium vivax and P. ovale for drug susceptibility testing. Parasitol Res 1994;80:262-4.
27. [27] Ofulla AVO, Okoye VCN, Khan B, et al. Cultivation of Plasmodium falciparum parasites in a serum-free medium. Am J Trop Med Hyg 1993;49:335-40.
28. [28] Matthews DA, Alden RA, Bolin JT, et al. Dihydrofolate reductase: X-ray structure of the binary complex with methotrexate. Science 1977;197:452-5.
29. [29] Bolin JT, Filman DJ, Matthews DA, Hamlin RC, Kraut J. Crystal structure of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. J Biol Chem 1982;257:13650-62.
30. [30] Volz KW, Matthews DA, Alden RA, et al. Crystal structure of avian dihydrofolate reductase containing phenyl-triazine and NADPH. J Biol Chem 1982;257:2528-36.
31. [31] Stammers DK, Champness JN, Beddell CR, et al. The structure of mouse L1210 dihydrofolate reductase-drug complexes and the construction of a model of human enzyme. FEBS Lett 1987;218:178-84.
32. [32] Hyde JE. Point mutations and pyrimethamine resistance in Plasmodium falciparum. Parasitol Today 1989;5:252-5.
33. [33] Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1990;87:3018-22.
34. [34] Sirawaraporn W, Sirawaraporn R, Cowman AF, Yuthavong Y, Santi DV. Heterologous expression of active thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry 1990;29:10779-85.
35. [35] Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 1997;94:1124-9.
36. [36] Foote SJ, Galatas D, Cowman AF. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 1990;87:3014-7.
37. [37] Wu Y, Kirkman LA, Wellems TE. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc Natl Acad Sci USA 1996;93:1130-4.